We present a case of intrabiliary primary B-cell lymphoma masked as a cholangiocarcinoma in an HIV-positive patient. The two entities have similar symptoms, laboratory findings, and imaging findings but require very different treatments. The case highlights the need to confirm the diagnosis by biopsy.
H IV-associated primary non-Hodgkin's lymphoma of the bile duct is an uncommon presentation of obstructive jaundice, with few published cases (1). With similar symptoms and laboratory and imaging fi ndings, bile duct lymphoma and cholangiocarcinoma can be almost identical (2). Since cholangiocarcinoma is far more prevalent than primary bile duct lymphoma, a presumed diagnosis of cholangiocarcinoma is often made before biopsy confi rmation (3)-an approach that raises concern since the two malignancies require radically diff erent treatment.
CASE REPORT
A 61-year-old HIV-infected man with a CD4 count of 77 mL presented to the emergency department with nausea, advanced disease, only emphasizing the importance of rapid diagnosis and initiation of correct treatment. As lymphoma is an AIDS-defi ning illness, its diagnosis in an HIV-infected patient is not only important for initiation of appropriate treatment but also serves a prognostic purpose. Th e diagnosis indicates an immunocompromised state, regardless of CD4 count, and the need for careful oversight of the patient's overall management.
area of the hilar bile duct without metastatic disease. Pretreatment evaluation is under way, with plans to initiate rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy.
DISCUSSION
Non-Hodgkin's lymphoma resulting in obstructive jaundice is primarily caused by extrahepatic lymphoma compressing the bile duct, causing a mass eff ect. Very rarely is obstructive jaundice due to primary bile duct lymphoma, as in this vignette (4). On imaging, intra-and extrahepatic bile duct dilation was noted. Essentially identical radiologic fi ndings may be found in the setting of cholangiocarcinoma.
Adequate biopsy is needed for defi nitive diagnosis, as the management and prognosis for cholangiocarcinoma and lymphoma are notably diff erent (5). Treatment for cholangiocarcinoma is surgical resection or gemcitabine-based chemotherapy. Lymphoma is more chemoresponsive, and management utilizes the R-CHOP regimen. In addition, a diagnosis of lymphoma carries a better overall prognosis than cholangiocarcinoma. Biliary obstruction in the setting of lymphoma correlates with a b 
